Analyst Michael Ulz from Morgan Stanley maintained a Buy rating on Tenaya Therapeutics and keeping the price target at $5.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Michael Ulz has given his Buy rating due to a combination of factors, primarily focusing on the promising developments in Tenaya Therapeutics’ key programs, TN-201 and TN-401. The company has made significant progress in its TN-201 program, which targets MYBPC3-associated hypertrophic cardiomyopathy. With the completion of enrollment in Cohort 2 and a favorable review from the Data Safety Monitoring Board, Tenaya is set to provide initial data updates in the fourth quarter of 2025, indicating a positive trajectory for the program.
Similarly, the TN-401 program, aimed at treating PKP2-associated arrhythmogenic right ventricular cardiomyopathy, has also shown progress with the completion of enrollment in its first cohort. The upcoming data release in the fourth quarter of 2025 is expected to include critical safety and biopsy results. Additionally, Tenaya’s strong cash position, projected to sustain operations into the second half of 2026, and their strategic initiatives, such as the upcoming KOL event, further support the Buy rating by highlighting the company’s robust financial health and commitment to advancing its therapeutic pipeline.